Guidelines for reporting case studies and series on drug-induced QT interval prolongation and its complications following acute overdose

References

• Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264.
   PubMedGoogle Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.
   PubMed Web of Science ®Google Scholar
• Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943–1948.
   PubMed Web of Science ®Google Scholar
• Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J. 2016;149:139–152.
   Web of Science ®Google Scholar
• Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625–1633.
   PubMed Web of Science ®Google Scholar
• Wisniowska B, Tylutki Z, Wyszogrodzka G, et al. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016;17:12.
   PubMed Web of Science ®Google Scholar
• Schade Hansen C, Pottegard A, Ekelund U, et al. Association between QTc prolongation and mortality in patients with suspected poisoning in the emergency department: a transnational propensity score matched cohort study. BMJ Open. 2018;8:e020036.
   PubMed Web of Science ®Google Scholar
• Al-Abri SA, Woodburn C, Olson KR, et al. Ventricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California. Am J Cardiovasc Drugs. 2015;15:43–50.
   PubMed Web of Science ®Google Scholar
• Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30:391–395.
   PubMed Web of Science ®Google Scholar
• Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4:101–105.
   PubMedGoogle Scholar
• Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 2012;125:859–868.
   PubMed Web of Science ®Google Scholar
• Meuleman C, Jourdain P, Bellorini M, et al. Citalopram and torsades de pointes. A case report. Arch Mal Coeur Vaiss. 2001;94:1021–1024.
   PubMedGoogle Scholar
• Ostrom M, Eriksson A, Thorson J, et al. Fatal overdose with citalopram. Lancet. 1996;348:339–340.
   PubMed Web of Science ®Google Scholar
• Jonasson B, Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int. 2002;126:1–6.
   PubMed Web of Science ®Google Scholar
• Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135–141.
   PubMed Web of Science ®Google Scholar
• Indermitte J, Beutler M, Bruppacher R, et al. Management of drug-interaction alerts in community pharmacies. J Clin Pharm Ther. 2007;32:133–142.
   PubMed Web of Science ®Google Scholar
• Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002;27:377–382.
   PubMed Web of Science ®Google Scholar
• Weingart SN, Toth M, Sands DZ, et al. Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med. 2003;163:2625–2631.
   PubMed Web of Science ®Google Scholar
• Woosley RL, Heise CW, Gallo T, et al. QT drugs list 1822 Innovation Park Dr., Oro Valley, AZ 85755: AZCERT, Inc. 2016. Available from: www.CredibleMeds.org [Accessed 10/1/2016]
   Google Scholar
• Hasnain M, Vieweg WV, Howland RH, et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv. 2014;4:130–138.
   PubMedGoogle Scholar
• Vieweg WV, Hasnain M, Hancox JC, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl). 2013;228:515–524.
   PubMed Web of Science ®Google Scholar
• Giancaterino S, Solimine S. Probable acquired QTc prolongation and subsequent torsades de pointes attributable to quetiapine. Prim Care Companion CNS Disord. 2017;19:23.
   Google Scholar
• Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet. 2007;46:897–939.
   PubMed Web of Science ®Google Scholar
• Chan A, Isbister GK, Kirkpatrick CM, et al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM. 2007;100:609–615.
   PubMed Web of Science ®Google Scholar
• Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2:38–43.
   PubMedGoogle Scholar
• Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Safety. 2007;30:367–373.
   PubMed Web of Science ®Google Scholar
• Lavergne V, Ouellet G, Bouchard J, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial. 2014;27:407–414.
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Hasnain M, Howland RH, et al. Methadone, QTc interval prolongation and torsade de pointes: case reports offer the best understanding of this problem. Ther Adv Psychopharmacol. 2013;3:219–232.
   PubMedGoogle Scholar
• Institute of Medicine (US) Committee on Standards from Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. Washington (DC): National Academies Press (US); 2011. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209539/
   Google Scholar
• Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28:887–920.
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535–2541.
   PubMed Web of Science ®Google Scholar
• Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J. 1997;18:1000–1006.
   PubMed Web of Science ®Google Scholar
• Huo J, Wei F, Cai C, et al. Sex-related differences in drug-induced QT prolongation and torsades de pointes: a new model system with human iPSC-CMs. Toxicol Sci. 2018;167:360–374.
   Web of Science ®Google Scholar
• Goutelle S, Sidolle E, Ducher M, et al. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study. Drugs Aging. 2014;31:601–609.
   PubMed Web of Science ®Google Scholar
• Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13:1085–1095.
   PubMed Web of Science ®Google Scholar
• Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001;24:323–351.
   PubMed Web of Science ®Google Scholar
• Wong LC, Behr ER. Acquired long QT syndrome: as risky as congenital long QT syndrome? Europace. 2012;14:310–311.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Kinirons MT, Swift CG, et al. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing. 2003;32:326–331.
   PubMed Web of Science ®Google Scholar
• Cupisti A, Galetta F, Caprioli R, et al. Potassium removal increases the QTc interval dispersion during hemodialysis. Nephron. 1999;82:122–126.
   PubMed Web of Science ®Google Scholar
• Chvilicek JP, Hurlbert BJ, Hill GE. Diuretic-induced hypokalaemia inducing torsades de pointes. Can J Anaesth. 1995;42:1137–1139.
   PubMed Web of Science ®Google Scholar
• Foglia PE, Bettinelli A, Tosetto C, et al. Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). Nephrol Dial Transplant. 2004;19:1398–1402.
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Bengtson J, Chen ZY, et al. Duration of the QT interval and total and cardiovascular mortality in healthy persons (the Framingham heart study experience). Am J Cardiol. 1991;67:55–58.
   PubMed Web of Science ®Google Scholar
• Hondeghem LM. Drug-induced QT prolongation and torsades de pointes: an all-exclusive relationship or time for an amicable separation? Drug Saf. 2018;41:11–17.
   PubMed Web of Science ®Google Scholar
• Diaz-Castro O, Puchol A, Almendral J, et al. Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. J Electrocardiol. 2004;37:55–60.
   PubMed Web of Science ®Google Scholar
• Rodan DM. Drug induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022.
   Google Scholar
• Yamagiwa T, Amino M, Morita S, et al. A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone and triazolam in a patient receiving nifedipine. Clin Toxicol (Phila). 2010;48:149–152.
   PubMed Web of Science ®Google Scholar
• Yamagiwa T, Morita S, Amino M, et al. Serum concentration of eperisone hydrochloride correlates with QT interval. Am J Emerg Med. 2014;32:75–77.
   PubMed Web of Science ®Google Scholar
• Othong R, Devlin JJ, Kazzi ZN. Medical toxicologists’ practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region. Clin Toxicol (Phila). 2015;53:204–209.
   PubMed Web of Science ®Google Scholar
• Isbister GK. How do we assess whether the QT interval is abnormal: myths, formulae and fixed opinion. Clin Toxicol (Phila). 2015;53:189–191.
   PubMed Web of Science ®Google Scholar
• Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002;48:3–9.
   PubMed Web of Science ®Google Scholar
• Rautaharju PM, Zhang ZM, Prineas R, et al. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol. 2004;93:1017–1021.
   PubMed Web of Science ®Google Scholar
• Othong R, Wattanasansomboon S, Kruutsaha T, et al. Utility of QT interval corrected by Rautaharju method to predict drug-induced torsade de pointes. Clin Toxicol (Phila) 2018;57:234–239.
   PubMed Web of Science ®Google Scholar
• Strauss DG, Vicente J, Johannesen L, et al. Common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk: a pilot study. Circulation. 2017;135:1300–1310.
   PubMed Web of Science ®Google Scholar
• Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S444–S464.
   PubMed Web of Science ®Google Scholar
• Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016;81:420–427.
   PubMed Web of Science ®Google Scholar
• Kallergis EM, Goudis CA, Simantirakis EN, et al. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal. 2012;2012:1.
   Google Scholar
• Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3:241–253.
   PubMedGoogle Scholar
• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American heart association and the American college of cardiology foundation. J Am Coll Cardiol. 2010;55:934–947.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Eckman MH, Schauer DP, et al. Cost-effectiveness of telemetry for hospitalized patients with low-risk chest pain. Acad Emerg Med. 2011;18:279–286.
   PubMed Web of Science ®Google Scholar